image

Linda Truong

Affiliate Investigator - Sydney Children’s Hospitals Network

Linda Truong (B.Sc (hons), M.Phil) is an experienced clinical trials project manager at the Sydney Children’s Hospitals Network and a qualified pharmacologist. Her expertise includes studying alternative pharmacotherapies affecting the brain and managing international and national multi-site industry sponsored and investigator-initiated Phase I-III clinical trials for both medicines and medical devices.

Linda also has an academic affiliation at the University of New South Wales in research and oversees the team driving inspection readiness activities related to assigned trials within the Refractory Epilepsy Program led by Dr John Lawson. She serves as the scientific and strategic leader of program and is accountable for scientific content, operational precision and integrity of development plans and ensuring protocols meet requirements for simultaneous regulatory submission and optimal research access.

She has over 15 years’ experience in leading and champions ideation and implementation of internal and external cross-functional innovation efforts to advance successful execution of research grants, clinical trials, patient-focused clinical trial design methodologies and technology solutions in Asia, Europe, Australia and New Zealand. Her key clinical therapeutic areas include: epilepsy, rheumatology, gastroenterology, ulcerative colitis, neurology, vaccine studies, ophthalmology, Ear Nose and Throat (ENT), osteoarthritis and endocrinology.

Linda serves as key member on the SCHN Refractory Epilepsy Steering Committee, External Review Committee and is currently managing the NSW Compassionate Access Scheme allowing children with treatment resistant epilepsy with Epidiolex ® and world first early phase clinical trial trialling Cannabidivarin in children with Rett Syndrome and epilepsy. She has developed regulatory and governance frameworks for conducting high quality clinical trials and an efficient model to implement consistent quality and risk frameworks to meet the requirements as a sponsor of trials and quality recognition by external bodies.

Linda aims to use her complimentary expertise in clinical trials management and cannabinoid research to capture safety and efficacy data that will be useful for ACRE to develop guidelines and policies on prescribing medicinal cannabis in the Australian research landscape. She believes that her skills fit within the interdisciplinary research program at ACRE, and concords with the ACRE's aspirations concerning the importance of engaged cannabinoid research that is relevant both nationally and internationally.